|November 4, 2012|
|12:25 EDT||AMGN||Amgen: Phase 3 EVOLVE trial results presented|
Amgen announced results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated treatment with Sensipar®/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular, CV, events among 3,883 patients with secondary hyperparathyroidism, HPT, and chronic kidney disease, CKD, receiving dialysis. The primary endpoint of the study was time to the composite event comprising all-cause mortality or first non-fatal CV event, including myocardial infarction, hospitalization for unstable angina, heart failure or peripheral vascular event. Although patients in the Sensipar/Mimpara arm experienced a seven percent reduction in the primary endpoint (Hazard Ratio 0.93, 95 percent CI 0.85 to 1.02, p=0.112), the results were not statistically significant, and the trial did not meet its primary endpoint in the intent-to-treat analysis. These data were published today in the New England Journal of Medicine and simultaneously presented at the American Society of Nephrology's Kidney Week.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
|December 6, 2013|
|08:31 EDT||AMGN||Amgen unit, International Myeloma Foundation announce partnership|
The International Myeloma Foundation and Onyx Pharmaceuticals, an Amgen subsidiary, announced the start of a multi-year collaboration in support of the IMF's Black Swan Research Initiative. The BSRI is led by a multinational consortium of leading myeloma experts who are studying and harnessing new technologies and treatments with the goal of developing a cure for myeloma.
|06:19 EDT||AMGN||Amgen price target lowered to $131 from $139 at Citigroup|
Citigroup lowered its price target for Amgen shares to $131 after dropping its estimates for the company's myeloma drug Kyprolis to below consensus. Citi believes the drug's inconvenience and cardiac toxicities are limiting its uptake and while drugs in late stage development offer far more appealing profiles. Citi, however, keeps a Buy rating on Amgen.
|December 3, 2013|
|09:37 EDT||AMGN||Active equity options trading on open|
Active equity options trading on open according to Track Data: CELG YHOO BX ARIA GS NXPI DG AMGN SLW MRK
|December 2, 2013|
|14:03 EDT||AMGN||Amgen pegfilgrastim granted orphan status for treatment of myelosuppression|
|November 27, 2013|
|13:05 EDT||AMGN||Amgen Neupogen granted orphan designation by FDA|
The drug received orphan designation for treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident. Reference Link
|November 26, 2013|
|16:14 EDT||AMGN||Amgen coverage resumed with an Overweight at Piper Jaffray|